This pig has picked up a lot of dead weight over the past 6 years of its decadent existence and is now wallowing at the bottom of the feed trough and lapping up remnants of overly fermented slop in the hope of surviving yet another year before being ignominously hauled off to the bacon factory. It will indeed take a miracle for this porker to sprout wings big enough to lift its huge ham hocks out of the mud in which it now seems to be inextricably and contently mired.
I just do not see how a small German company doing an IPO for sustaining its own operations will serve to directly and significantly impact DNAG's pps in a positive manner. All that expected IPO cash will most likely be exhausted within a year or so by the cost intensive procedures required by Biofrontera for completing the clinical trials and jumping through the regulatory hoops for commercializing those skin drugs.
The pumpers here cheer the possibility that DNAG will benefit from any scraps that might fall of the celebration table. I certainly do not see the Biofrontera managers whipping out their checkbook and asking our happy managers how much do they will need to attach wings to our ponderous porcine, even after downing many bratwursts and chugalugging a few tankards of their local brewski.
Market Data 
Markets 
AI
